Haemonetics earnings release, August 6, 2026

Haemonetics Corp (HAE) · Form 8-K, Item 2.02 · Filed · SEC filing

Haemonetics R eports First Quarter Fiscal 2027 Results;

Raises Total Company Fiscal 2027 Guidance

Boston,

MA, August 6, 2026

-

Haemonetics Corporation (NYSE: HAE) reported financial results for its first quarter of fiscal 2027, which ended June 27, 2026:

__________

(1)

Excludes the impacts of currency fluctuation and the exit of certain liquid solution products.

Chris Simon, Haemonetics’ CEO, stated: “We had a strong start to fiscal 2027, gaining Plasma share, sustaining Blood Management Technologies momentum, and returning Interventional Technologies to growth. With our evolved portfolio, transformed operating model and disciplined execution, we are strengthening our competitive position and demonstrating the durable growth of our diversified businesses. We raised full-year guidance, and Haemonetics is well-positioned to deliver sustainable long-term growth and shareholder value.”¹

GAAP RESULTS

First quarter fiscal 2027 revenue was $339.4 million, up 5.6% compared with the first quarter of fiscal 2026. Business unit revenue and growth rates compared with the prior year period were as follows:

Gross margin was 59.8% in the first quarter of fiscal 2027, which was relatively flat when compared with 59.8% in the first quarter of fiscal 2026. Operating expenses were $145.3 million, up $7.0 million, or 5.0%, compared with the first quarter of fiscal 2026. The increase in operating expenses was driven by higher personnel-related costs and freight charges. The Company had operating income of $57.5 million and a 16.9% operating margin in the first quarter of fiscal 2027, compared with operating income of $53.9 million and a 16.8% operating margin in the first quarter of fiscal 2026. The effective income tax rate was 30.6% in the first quarter of fiscal 2027, compared with 24.7% in the first quarter of fiscal 2026. The increase in the effective income tax rate was primarily driven by stock compensation shortfalls and valuation allowance impacts related to losses in certain recently acquired jurisdictions. First quarter fiscal 2027 net income and earnings per diluted share were $33.0 million and $0.72, respectively, compared with $34.0 million and $0.70, respectively, in the first quarter of fiscal 2026.

ADJUSTED RESULTS

First quarter organic revenue growth was

5.9% compared with the same period of fiscal 2026. Year-over-year organic revenue growth rates by business unit were as follows:

First quarter fiscal 2027 adjusted gross margin was 60.4%, down 40 basis points compared with the prior year period. The primary drivers of the decrease in the adjusted gross margin percentage included upfront revenue recognition upon the execution of a long-term software agreement in the prior year, partially offset by the continued transformation of the product portfolio to higher-margin offerings and benefits from product innovation.

Adjusted operating expenses were $125.6 million, up $7.9 million, or 6.7%, compared with the first quarter of fiscal 2026. The increase in adjusted operating expenses was driven by higher personnel-related costs and freight charges. Adjusted operating income for the first quarter of fiscal 2027 was $79.3 million, down $1.7 million, or 2.2%, compared with the first quarter of fiscal 2026. Adjusted operating margin was 23.4%, down 70 basis points when compared with the same period of fiscal 2026. The adjusted income tax rate for the first quarter of fiscal 2027 was 25.7%, up 180 basis points when compared with 24.9% in the first quarter of fiscal 2026. The increase in the effective income tax rate was primarily driven by stock compensation shortfalls.

First quarter fiscal 2027 adjusted net income was $52.3 million, up $0.9 million, or 1.8%, and adjusted earnings per diluted share was $1.14, up 3.6%, each when compared with the same period of fiscal 2026.

Financial statements

Income Statement

First Quarter Fiscal 2027 Reported (in millions)

First Quarter Fiscal 2027 ReportedFirst Quarter Fiscal 2027 Reported
Apheresis191.35.3%
MedSurg148.16.0%
Total net revenue339.45.6%

Income Statement

First Quarter Fiscal 2027 — with the same period of fiscal 2026. Year-over-year organic revenue growth rates by business unit were as follows:

First Quarter Fiscal 2027 – Organic
Apheresis6.0%
MedSurg5.9%
Total net revenue5.9%

Income Statement

Three Months Ended – 6/27/2026 – (Dollars and Shares in Thousands, Except Per Share Data)6/28/2025Inc/(Dec) %
Condensed Consolidated Statements of Income (Unaudited)Net revenues5.6%
Condensed Consolidated Statements of Income (Unaudited)Cost of goods sold136,577129,1505.8%
Condensed Consolidated Statements of Income (Unaudited)Gross profit202,803192,2445.5%
Condensed Consolidated Statements of Income (Unaudited)Research and development16,20016,261-0.4%
Condensed Consolidated Statements of Income (Unaudited)Selling, general and administrative118,941110,7197.4%
Condensed Consolidated Statements of Income (Unaudited)Amortization of acquired intangible assets10,20411,392-10.4%
Condensed Consolidated Statements of Income (Unaudited)Total Operating expenses145,345138,3725.0%
Condensed Consolidated Statements of Income (Unaudited)Operating income57,45853,8726.7%
Condensed Consolidated Statements of Income (Unaudited)Interest and other expense, net-9,884-8,70313.6%
Condensed Consolidated Statements of Income (Unaudited)Income before provision for income taxes47,57445,1695.3%
Condensed Consolidated Statements of Income (Unaudited)Provision for income taxes14,56411,13830.8%
Condensed Consolidated Statements of Income (Unaudited)Net income-3.0%
Condensed Consolidated Statements of Income (Unaudited)Net income per common share assuming dilution2.9%
Weighted average shares outstandingBasic45,36148,111
Weighted average shares outstandingDiluted45,70448,353
Weighted average shares outstandingProfit Margins:Inc/(Dec) %
Weighted average shares outstandingGross profit59.859.8—%
Weighted average shares outstandingResearch and development4.85.1-0.3%
Weighted average shares outstandingSelling, general and administrative3534.40.6%
Weighted average shares outstandingOperating income16.916.80.1%
Weighted average shares outstandingIncome before provision for income taxes1414.1-0.1%
Weighted average shares outstandingNet income9.710.6-0.9%

Income Statement

Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the MedSurg business unit.

Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Gross profitGross profitReconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Gross profitGross profitReconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Operating expensesOperating expensesReconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Operating expensesOperating expensesReconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Operating income (loss)Operating income (loss)Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Operating income (loss)Operating income (loss)Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Interest and other expenseInterest and other (expense) incomeReconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Interest and other expenseInterest and other (expense) incomeReconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Provision (benefit) for income taxesProvision (benefit) for income taxesReconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Provision (benefit) for income taxesProvision (benefit) for income taxesReconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Net income (loss)Net income (loss)Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Net income (loss)Net income (loss)Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Earnings per diluted shareEarnings per diluted shareReconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Earnings per diluted shareEarnings per diluted share
Reported202,803145,34557,458-9,88414,56433,0100.72
Amortization of acquired intangible assets-10,20410,2042,2857,9190.16
Integration and transaction costs1,285-1,4342,719-4233,1420.07
Restructuring costs783-1,5152,2985371,7610.04

Balance Sheet

Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the MedSurg business unit.

Condensed Consolidated Balance Sheets (Unaudited) – June 27, 2026Condensed Consolidated Balance Sheets (Unaudited) – March 28, 2026
AssetsCash and cash equivalents223,384245,440
AssetsAccounts receivable, net216,071216,855
AssetsInventories, net306,739306,370
AssetsOther current assets64,63866,214
AssetsTotal current assets810,832834,879
AssetsProperty, plant & equipment, net303,778305,761
AssetsIntangible assets, net434,512447,655
AssetsGoodwill656,884656,368
AssetsOther assets159,394151,262
AssetsTotal assets2,365,4002,395,925
Liabilities & Stockholders' EquityShort-term debt & current maturities4,9565,015
Liabilities & Stockholders' EquityOther current liabilities258,279277,584
Liabilities & Stockholders' EquityTotal current liabilities263,235282,599
Liabilities & Stockholders' EquityLong-term debt1,169,2021,219,565
Liabilities & Stockholders' EquityOther long-term liabilities95,86297,441
Liabilities & Stockholders' EquityStockholders' equity837,101796,320
Liabilities & Stockholders' EquityTotal liabilities & stockholders' equity2,365,4002,395,925

Cash Flow

Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the MedSurg business unit.

Condensed Consolidated Statements of Cash Flows (Unaudited) – Three Months Ended – June 27, 2026
Cash Flows from Operating Activities:Net income33,010
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization27,111
Adjustments to reconcile net income to net cash provided by operating activities:Share-based compensation expense9,311
Adjustments to reconcile net income to net cash provided by operating activities:Deferred income taxes668
Adjustments to reconcile net income to net cash provided by operating activities:Change in other non-cash operating activities2,227
Change in operating assets and liabilities:Change in accounts receivable, net297
Change in operating assets and liabilities:Change in inventories, net-1,004
Change in operating assets and liabilities:Change in prepaid income taxes6,101
Change in operating assets and liabilities:Change in other assets and other liabilities-12,783
Change in operating assets and liabilities:Change in accounts payable and accrued expenses-12,615
Change in operating assets and liabilities:Net cash provided by operating activities52,323
Cash Flows from Investing Activities:Capital expenditures-7,906
Cash Flows from Investing Activities:Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment-5,565
Cash Flows from Investing Activities:Proceeds from sale of property, plant and equipment237
Cash Flows from Investing Activities:Other investments-9,000
Cash Flows from Investing Activities:Net cash used in investing activities-22,234
Cash Flows from Financing Activities:Repayments, net of borrowings-51,563
Cash Flows from Financing Activities:Proceeds from employee stock programs3,549

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.